Skip to content
Biodatica
Start free

Copenhagen Respiratory Research

Rønne, Bornholm

OncologyFiled/Approved
Compare Sign in to watch

What changed

Filed/Approved trial registered: Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

4mo agoTrial registeredMar 18, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Momentum 91 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

62 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Mar 10, 2026

    Community Acquired Pneumonia (CAP) · RECRUITING · sponsor: Copenhagen Respiratory Research · Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

    ClinicalTrials.gov · NCT06892197 (opens the source filing in a new tab)

  2. Patent

    Patent granted

    Jan 7, 2025

    assignee: Aarhus Universitet · GENETICALLY ALTERED LYSM RECEPTORS WITH ALTERED AGONIST SPECIFICITY AND AFFINITY

    USPTO · US 12190997 (opens the source filing in a new tab)

  3. Patent

    Patent assigned

    Feb 9, 2024

    assignee: AARHUS UNIVERSITET · GENETICALLY ALTERED LYSM RECEPTORS WITH ALTERED AGONIST SPECIFICITY AND AFFINITY

    USPTO · US 12190997 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Dec 28, 2023

    Urinary Bladder Neoplasms · COMPLETED · sponsor: Jørgen Bjerggaard Jensen · GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit

    ClinicalTrials.gov · NCT06281691 (opens the source filing in a new tab)

  5. Trial

    NA registered

    Feb 1, 2023

    Bladder Cancer · RECRUITING · sponsor: Aarhus University Hospital · Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy

    ClinicalTrials.gov · NCT05679557 (opens the source filing in a new tab)

  6. Trial

    PHASE4 registered

    Feb 3, 2021

    Side Effect of Drug · ACTIVE_NOT_RECRUITING · sponsor: Jørgen Bjerggaard Jensen · NORTH-REG Dwell-Time Study

    ClinicalTrials.gov · NCT04701151 (opens the source filing in a new tab)

  7. Trial

    PHASE4 registered

    Nov 1, 2017

    Bladder Cancer · COMPLETED · sponsor: Jørgen Bjerggaard Jensen · Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

    ClinicalTrials.gov · NCT03348969 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources